Literature DB >> 12937019

Real-time PCR as a versatile tool for investigating the susceptibility of human herpesvirus 6 to antiviral agents.

Muriel Macé1, Chaysavanh Manichanh, Pascale Bonnafous, Stéphanie Précigout, David Boutolleau, Agnès Gautheret-Dejean, Henri Agut.   

Abstract

A quantitative real-time PCR assay was developed for the determination of antiviral drug susceptibility and growth kinetics of human herpesvirus 6. The susceptibility and fitness of a sensitive strain, HST, and its ganciclovir-resistant derivative, GCVR1, were then characterized, leading us to conclude that the mutations of this latter virus did not alter its fitness significantly.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12937019      PMCID： PMC182648          DOI： 10.1128/AAC.47.9.3021-3024.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients.

Authors:  D V Ablashi; H B Eastman; C B Owen; M M Roman; J Friedman; J B Zabriskie; D L Peterson; G R Pearson; J E Whitman
Journal:  J Clin Virol       Date:  2000-05       Impact factor: 3.168

2.  Development of a real-time polymerase chain reaction assay for the diagnosis of human herpesvirus-6 infection and application to bone marrow transplant patients.

Authors:  Agnès Gautheret-Dejean; Chaysavanh Manichanh; Florence Thien-Ah-Koon; Anne-Marie Fillet; Nicole Mangeney; Michel Vidaud; Nathalie Dhedin; Jean-Paul Vernant; Henri Agut
Journal:  J Virol Methods       Date:  2002-02       Impact factor: 2.014

3.  (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays showed a lack of toxicity of ganciclovir (GCV), C.OXTs, and their derivatives, to TaY(OK) cells at 1 microM. Therefore we compared the antiviral potencies of these drugs at 1 microM by monitoring the viral loads produced during a 1-day period during the course of the drug treatment. Among the drugs tested, 3'-fluorocarbocyclic oxetanocin A (3'F-C.OXT-A) was the most effective for inhibiting the virus production, and at concentrations ranging from 0.5 microM to 10 microM, the inhibition of the viral production was dose-dependent. A comparison of the chemical structures of the derivatives with that of C.OXT-A, which is the parental molecule, suggested that the 3'-fluorine-modification might account for the higher anti-HHV-6 activity and lower cytotoxicity.

Authors:  P Wang; K Abe; T Ojima; J H Ohyashiki; H Satoh; T Maruyama; H Nagata; H Tanaka; K Yamamoto
Journal:  Microbiol Immunol       Date:  2001       Impact factor: 1.955

4.  In vitro sensitivity of human herpesvirus-6 to antiviral drugs.

Authors:  H Agut; H Collandre; J T Aubin; D Guétard; V Favier; D Ingrand; L Montagnier; J M Huraux
Journal:  Res Virol       Date:  1989 May-Jun

5.  Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo.

Authors:  Chaysavanh Manichanh; Camille Olivier-Aubron; Jean-Pierre Lagarde; Jean-Thierry Aubin; Phillipe Bossi; Agnès Gautheret-Dejean; Jean-Marie Huraux; Henri Agut
Journal:  J Gen Virol       Date:  2001-11       Impact factor: 3.891

6.  Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients.

Authors:  David Boutolleau; Caroline Fernandez; Elisabeth André; Berthe-Marie Imbert-Marcille; Noël Milpied; Henri Agut; Agnès Gautheret-Dejean
Journal:  J Infect Dis       Date:  2003-01-06       Impact factor: 5.226

7.  Selection and characterization of two specific monoclonal antibodies directed against the two variants of human herpesvirus-6.

Authors:  C Robert; V Massonneau; P Pothier; A Clément; G Hejblum; P Hubert; J T Aubin; H Agut
Journal:  Res Virol       Date:  1998 Nov-Dec

8.  Identification of human herpesvirus-6 as a causal agent for exanthem subitum.

Authors:  K Yamanishi; T Okuno; K Shiraki; M Takahashi; T Kondo; Y Asano; T Kurata
Journal:  Lancet       Date:  1988-05-14       Impact factor: 79.321

9.  Application of real-time PCR for determination of antiviral drug susceptibility of herpes simplex virus.

Authors:  Růzena Stránská; Anton M van Loon; Merjo Polman; Rob Schuurman
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Inhibition of human herpesvirus 6 replication by 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (2HM-HBG) and other antiviral compounds.

Authors:  A Akesson-Johansson; J Harmenberg; B Wahren; A Linde
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191
View more
  4 in total

1.  Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay.

Authors:  Kaoru Wada; Naomi Kubota; Yoshinori Ito; Hiroshi Yagasaki; Koji Kato; Tetsushi Yoshikawa; Yasuyuki Ono; Hisami Ando; Yasuhiro Fujimoto; Tetsuya Kiuchi; Seiji Kojima; Yukihiro Nishiyama; Hiroshi Kimura
Journal:  J Clin Microbiol       Date:  2007-03-21       Impact factor: 5.948

2.  Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro.

Authors:  Parmjeet Randhawa; Noush Afarin Farasati; Ron Shapiro; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Evaluation of Epstein-Barr virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays.

Authors:  Lotfi Bounaadja; Jocelyne Piret; Nathalie Goyette; Guy Boivin
Journal:  J Clin Microbiol       Date:  2013-01-16       Impact factor: 5.948

4.  Reply to "Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays".

Authors:  Lotfi Bounaadja; Jocelyne Piret; Nathalie Goyette; Guy Boivin
Journal:  J Clin Microbiol       Date:  2013-06       Impact factor: 5.948
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.